For instance, approximately half of KRASG12D driven lung cancers inactivate LKB1. 46In addition to KRAS, LKB1 is often co-mutated with TP5347 and KEAP1. 48From a clinical standpoint, understanding the synergy of LKB1 co-mutants may predict patient prognosis as the overall survival of patients with LKB1/KRAS co-mutant tumors is poor compared with other LKB1 co-mutant tumors.47 This evidence concerns the gene KRAS and lung cancer.